Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Molecularly targeted therapy for melanoma: current reality and future options Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild ACancer 2006[Nov]; 107 (10): 2317-27Effective therapy for melanoma remains an unmet goal, with most traditional therapies representing inadequate trade-offs among the several goals of specificity, efficacy, and toxicity. Targeted molecular therapeutics are tailored to genetic abnormalities that are associated with tumor progression. Modulation of aberrant signaling pathways in cancer cells has the potential to provide more effective and potentially nontoxic therapy for a broad range of cancers, including melanoma. Among the possible targets in melanoma are the Ras-MAPK and PI3K/AKT signal transduction pathways, the proteasome, histone deacetylases, methyltransferases, and melanoma-induced angiogenesis.|Angiogenesis Inhibitors/therapeutic use[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Apoptosis/drug effects[MESH]|Drug Resistance, Neoplasm[MESH]|Genes, Tumor Suppressor/physiology[MESH]|Humans[MESH]|Melanoma/*drug therapy/genetics[MESH]|Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors[MESH]|Models, Biological[MESH]|Phosphoinositide-3 Kinase Inhibitors[MESH]|Proteasome Inhibitors[MESH]|Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors[MESH]|Signal Transduction[MESH]|Skin Neoplasms/*drug therapy/genetics[MESH] |